Flubromazepam initially synthesised in 1960 but never officially marketed or extensively studied, resurfaced in late 2012 within the grey market as an emerging designer drug. This benzodiazepine derivative gained renewed attention and interest.
Structurally, it bears a resemblance to phenazepam, with the notable substitution of a chlorine atom for a fluorine atom.
It’s worth noting that an alternative isomer, known as “iso-flu bromazepam,” with the chemical name 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one, may have been distributed under the same name, further adding to the complexity of its emergence.

IUPAC name
CAS Number2647-50-9 
PubChem CID12947024
CompTox Dashboard (EPA)DTXSID40513609
Chemical and physical data
Molar mass333.160 g·mol−1

Legal status

United Kingdom
Flubromazepam was designated as a Class C drug in the United Kingdom during the May 2017 revision of The Misuse of Drugs Act 1971, aligning it with other designer benzodiazepine drugs.
United States
In the United States, Virginia State Law has categorized flubromazepam, along with clonazolam and flubromazolam, as Schedule I controlled substances.


  • What is Flubromazepam?
  • Flubromazepam is a designer drug and a benzodiazepine derivative. It was initially synthesized in 1960 but gained attention in the grey market as a designer drug around 2012. It belongs to a class of compounds known for their sedative and anxiolytic effects.
  • How does Flubromazepam work?
  • Flubromazepam, like other benzodiazepines, acts on the central nervous system by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA). This action results in reduced anxiety, muscle relaxation, and sedation.
  • Is Flubromazepam legal?
  • The legal status of Flubromazepam varies by country and region. In the United Kingdom, it is classified as a Class C drug under the Misuse of Drugs Act 1971. In the United States, it is listed as a Schedule I controlled substance in Virginia.
  • Are there any analogues or related compounds to Flubromazepam?
  • Flubromazepam has an analog known as “iso-flubromazepam.” This alternate isomer may have been sold under the same name.
  • What are the effects of Flubromazepam?
  • Flubromazepam is known for its sedative and anxiolytic effects. It can induce feelings of relaxation and reduce anxiety. However, its use is associated with potential risks and side effects, especially when not used as prescribed.
  • Is Flubromazepam safe to use?
  • The safety of Flubromazepam is a subject of concern, as it has not undergone the rigorous testing and research required for medical approval. Its use can lead to adverse effects, including dependence and withdrawal symptoms.
  • Is Flubromazepam addictive?
  • Like other benzodiazepines, Flubromazepam has the potential for addiction, especially when used regularly and in higher doses. Abrupt discontinuation can lead to withdrawal symptoms.
  • What is the recommended dosage of Flubromazepam?
  • Flubromazepam should not be used without medical supervision. If prescribed, the dosage will be determined by a healthcare professional based on an individual’s specific needs and condition.
  • Can I purchase Flubromazepam legally?
  • The legality of obtaining Flubromazepam depends on your location. It is essential to be aware of the laws and regulations in your country or region regarding this substance.
  • Are there any medical uses for Flubromazepam?
  • Flubromazepam is not approved for medical use in most countries. It is primarily found on the grey market as a designer drug and is not prescribed by healthcare providers.
  • What are the risks associated with Flubromazepam use?
  • Risks associated with Flubromazepam use include the potential for addiction, withdrawal symptoms, and adverse effects on physical and mental health. Misuse or abuse of the substance can be harmful.
  • Is there ongoing research on Flubromazepam?
  • Research on designer benzodiazepines like Flubromazepam is limited due to their legal status and potential risks. Monitoring and studying such substances are crucial for understanding their effects and ensuring public safety.


  1. US Patent 3136815 – “Amino Substituted Benzophenone Oximes and Derivatives Thereof”
  2. In November 2013, a study by Moosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, and Auwärter V was published in the “Journal of Mass Spectrometry” (Volume 48, Issue 11) with the title “Detection and Identification of the Designer Benzodiazepine Flubromazepam and Preliminary Data on Its Metabolism and Pharmacokinetics.” The study can be accessed via DOI: 10.1002/jms.3279, and it has the PMID: 24259203.
  3. Moosmann B, Hutter M, Huppertz LM, and Auwärter V conducted research on the characterization of the designer benzodiazepines pyrazolam and flubromazepam, as well as their detectability in human serum and urine samples. This study is available as a PDF from the Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany.
  4. In March 2016, O’Connor LC, Torrance HJ, and McKeown DA published a study titled “ELISA Detection of Phenazepam, Etizolam, Pyrazolam, Flubromazepam, Diclazepam, and Delorazepam in Blood Using Immunalysis® Benzodiazepine Kit” in the “Journal of Analytical Toxicology” (Volume 40, Issue 2). The study can be accessed via DOI: 10.1093/jat/bkv122, and it has the PMID: 26518230.
  5. Information on “Flubromazepam” can be found in the “New Synthetic Drugs Database.”
  6. Pettersson Bergstrand M, Helander A, Hansson T, and Beck O conducted a study in April 2017 on the detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. This research was published in “Drug Testing and Analysis” (Volume 9, Issue 4) with the DOI: 10.1002/dta.2003, and it has the PMID: 27366870.
  7. In November 2016, Høiseth G, Tuv SS, and Karinen R conducted a study on the blood concentrations of new designer benzodiazepines in forensic cases, which was published in the “Forensic Science International” (Volume 268) with the DOI: 10.1016/j.forsciint.2016.09.006, and it has the PMID: 27685473.
  8. Manchester KR, Maskell PD, and Waters L conducted research on the affinity and plasma protein binding values for benzodiazepines that appear as new psychoactive substances. This study is available as a PDF in “Drug Testing and Analysis.”
  9. Baumeister D, Tojo LM, and Tracy DK published a paper in April 2015 titled “Legal Highs: Staying on Top of the Flood of Novel Psychoactive Substances” in “Therapeutic Advances in Psychopharmacology” (Volume 5, Issue 2). The study can be accessed via DOI: 10.1177/2045125314559539, and it is available on PMC with PMC ID: 4521440. The PMID is 26240749.
  10. Information regarding “The Misuse of Drugs Act 1971 (Amendment) Order 2017” can be found on Legislation.gov.uk.
  11. “Administrative Code 18VAC110-20-322” contains details about the placement of chemicals in Schedule I and is relevant to Virginia Law.

Leave a Comment

Your email address will not be published. Required fields are marked *